avatrombopag: a novel oral therapy for the treatment of itp
Published 6 years ago • 1.5K plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:29
novel promising agents for the treatment of itp
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
1:59
novel investigational drugs and promising therapies for immune thrombocytopenia
-
4:14
long-term safety and efficacy of sutimlimab for chronic itp
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
2:02
how to ace your rheumatology interview
-
1:06:04
itp: novel treatments
-
8:19
idiopathic thrombocytopenic purpura (itp) -pathophysiology, clinical features, diagnosis & treatment
-
1:55
latest updates in the management of immune thrombocytopenia
-
3:23
session overview: improving treatment for patients with itp
-
3:17
thrombopoietin receptor agonists in itp: current status and future outlooks
-
1:20
haemstar uk-wide “flash-mob” audit of ivig use in itp
-
4:43
novel treatments being explored for patients with hemophilia: highlights from isth 2024
-
1:26
avatrombopag, rilzabrutinib and covid-19 updates in itp
-
1:05
reprogramming leukemia cells into apcs as a novel therapeutic strategy for b-all
-
1:09
emerging treatment options for refractory immune thrombocytopenia
-
1:19
the potential of caplacizumab in the treatment of attp
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:46
updated analyses from the pathfinder trial: avapritinib therapy in advanced systemic mastocytosis